[A24-116] Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V
Last updated 04.03.2025
Project no.:
A24-116
Commission:
Commission awarded on 29.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide
- Patients with 1 to 3 prior therapies for whom daratumumab in combination with pomalidomide and dexamethasone (DPd) or pomalidomide in combination with bortezomib and dexamethasone (PVd) is a suitable individualized therapy: hint of a non-quantifiable added benefit
- Patients with 1 to 3 prior therapies for whom DPd or PVd is not a suitable individualized therapy, and patients with ≥ 4 prior therapies: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-116
| Project no. | Title | Status |
|---|---|---|
| G23-04 | Ciltacabtagene autoleucel (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |